The Infinium Global Research analyzes the Pompe Disease Treatment Market over the period of 2019 to 2025. This report also provides detailed qualitative and quantitative analyses of the market dynamics, market size and future trends in global pompe disease treatment market. It will help a lot of decision makers to develop strategies and find new opportunities in the global markets of pompe disease treatment. The report covers market changing aspects including drivers, restraints, opportunities, and trends expected to encouragement the expansion of the pompe disease treatment market during the period.
“We are Now Including the Impact Analysis of the COVID-19 on this Premium Report and the Forecast Period of this Report shall be Revised to 2020-2026.” The Section on the Impact of COVID-19 on this Market is Included in the Report for Free. To Know More Request Sample of this Report: https://www.infiniumglobalresearch.com/reports/sample-request/13396
Pompe disease is a progressive disease that gets worse over time. This disease causes progressive muscle weakness and often leads to breathing problems. Pomp disease is also considered as a metabolic muscle disease. It is similar to other neuromuscular disorders such as muscular dystrophies. The symptoms of Pompe disease are insufficient or missing amounts of an enzyme called acid alpha-glucosidase (GAA). This enzyme is needed to break down a complex sugar molecule into glucose.
Audentes Therapeutics intended AT845 to provide long-term production of an enzyme
In January 2019, Audentes Therapeutics Planned to File Investigational New Drug Application for Potential Pompe disease gene therapy AT845.The AT845 is intended to provide long-term production of an enzyme called acid alpha-glucosidase (GAA) that required to break down glycogen into glucose. Pompe disease is caused by mutations in the GAA gene, which impair the activity or production of the enzyme.
Emerging Immunotherapeutic Approaches for Pompe Disease Provide Growth Opportunities for Pompe Disease Treatment Market
Growing prevalence of pompe disease among population, Enzyme replacement therapies and growing developments in gene therapy are driving the growth of the Pompe disease treatment market. However, expensive therapy treatments is hindering the growth of the market. Moreover, emerging immunotherapeutic approaches for Pompe disease provide growth opportunities for pompe disease treatment market.
The Pompe disease treatment market is segmented into therapy type, molecule type, route of administration and dosage forms. On the basis of therapy type, it is segmented into enzyme replacement therapy and substrate reduction therapy. On the basis of molecule type, it is consists of biologics and small molecules. On the basis of the route of administration, it involves oral and parenteral. The Pompe disease treatment market on basis of dosage forms bifurcated into solid and liquid.
North America is the Largest Region for Global Pompe Disease Treatment Market
The pompe disease treatment market based on region segmented into North America, Europe, the Asia Pacific and the RoW. North America is the largest region for global Pompe disease treatment market. Asia Pacific is expected to grow with healthy CAGR owing to healthcare facilities and increasing awareness among patients regarding rare disorders.
The key players in the global pompe disease treatment market are BioMarin Pharmaceutical, Amicus Therapeutics, Genzyme company, Oxyrane, Audentes Therapeutics, Sangamo BioSciences, EpiVax, and Valerion Therapeutics.
Reasons to Buy this Report:
- Comprehensive analysis of global as well as regional markets of the pompe disease treatment.
- Complete coverage of all the product type and applications segments to analyze the trends, developments, and forecast of market size up to 2025.
- Comprehensive analysis of the companies operating in this market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.
- Infinium Global Research- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.